Comparison Between One Injection and Three Monthly Injections of Intervitreal Bevacizumab for Myopic Choroidal Revascularization

Abstract

Purpose: : To compare one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization (mCNV).

Methods: : Nineteen eyes of 19 patients with mCNV were treated with intravitreal bevacizumab injections. Group A included 10 patients treated with three monthly intravitreal bevacizumab (1.25 mg) injections. Group B included nine patients treated with one intravitreal bevacizumab injection. All patients were followed for 6 months from the last injection. The best-corrected visual acuity (BCVA) and the central foveal thickness (CFT) on optical coherence tomography were evaluated.

Results: : The mean logMAR BCVA at baseline was 0.66 in group A and 0.64 in group B. The mean BCVA improved to 0.34 at 6 months in group A (p=0.016) and to 0.44 in group B. There was no significant difference between the two groups (p=0.053). The mean CFT decreased from 328 µm at baseline to 173 µm in group A (p=0.004) and from 301 µm to 195 µm group B (p=0.027). The changes in BCVA and in CFT did not different between the groups. Additional injections for 6 months after the last injection were required in one of 10 eyes in group A and four of nine eyes in group B.

Conclusions: : Intravitreal bevacizumab injections improved the BCVA and CFT. Treatment starting with three monthly injections of bevacizumab may require fewer retreatments compared with an initial single injection of bevacizumab.

Keywords: myopia • choroid: neovascularization • vascular endothelial growth factor